At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 21, 2026 at 16:49 ET
Telix Pharmaceuticals announced that safety and dosimetry data from Part 1 of its Phase 3 ProstACT Global trial for TLX591-Tx will be presented as a late-breaking oral presentation at the 2026 ASCO Annual Meeting. The selection for a high-profile session underscores the potential clinical relevance of its radiopharmaceutical therapy in metastatic castration-resistant prostate cancer.
- Safety and dosimetry data from Part 1 of the ProstACT Global Phase 3 trial will be presented at ASCO 2026 as a late-breaking oral presentation.
- Part 1 included 36 patients and assessed tolerability, biodistribution, and radiation dose profile of TLX591-Tx in combination with standard of care.
- TLX591-Tx shows reduced kidney toxicity and minimal salivary/lacrimal gland uptake compared to other PSMA-targeted therapies.
- The abstract was selected for a high-visibility session at ASCO, indicating strong interest from the oncology community.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access